Get startedLog in
    Picture of Vanda Pharmaceuticals logo

    VNDA — Vanda Pharmaceuticals News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareAdventurousSmall CapNeutral
    All News

    Brief: Vanda Pharmaceuticals US Availability Of Nereus For People With Motion Sickness

    Picture of Vanda Pharmaceuticals logoVanda Pharmaceuticals
    01/05/2026 21:43
    May 1 (Reuters) - Vanda Pharmaceuticals Inc VNDA.O:

VANDA PHARMACEUTICALS ANNOUNCES U.S. COMMERCIAL AVAILABILITY OF NEREUS™ (TRADIPITANT), THE FIRST NEW PHARMACOLOGIC TREATMENT FOR PEOPLE WITH MOTION SICKNESS IN MORE THAN 40 YEARS

VANDA PHARMACEUTICALS: PATIENTS WITH VALID PRESCRIPTION CAN ACCESS NEREUS AT CASH-PAY PRICE OF $85 PER DOSE

VANDA PHARMACEUTICALS: STANDARD LIST PRICE OF $255 PER DOSE FOR NEREUS

VANDA PHARMACEUTICALS INC - NEREUS AVAILABLE VIA DIRECT-TO-CONSUMER PLATFORM AT NEREUS.US AT CASH-PAY PRICE OF $85 PER DOSE

Source text: ID:nPnsC7QTa

Further company coverage: VNDA.O

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Vanda Pharmaceuticals

    See all news